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Glucocorticoids, which have been implied inmoodmodulation, display robust diurnal oscillations in
the blood. But does their circadian rhythm regulate mood swings? Ikeda et al. now identify a para-
crine signaling pathway in the adrenal cortex that potentiates the daily amplitude of plasma gluco-
corticoids and renders female mice braver.Glucocorticoids (GCs) can act as stress
hormones and modulate multiple, seem-
ingly unrelated phenotypic and psycho-
logical traits, including mood and other
emotional behaviors (Holsboer and Ising,
2010). Produced in the adrenal gland
and secreted into the bloodstream, GCs
oscillate in a daily manner, and their levels
peak at the beginning of the activity phase
(that is, in the morning for humans and
in the evening for laboratory rodents).
When GC oscillations are perturbed, mis-
regulation of the dependent biological
processes is expected. However, it re-
mains unknown whether specific features
of these oscillations (period length, ampli-
tude, and phase) are causally linked to
specific behaviors. In this issue, Ikeda
et al. (2013) propose that variations in
the daily amplitude of GC levels influence
anxiolytic behavior in mice. The underly-
ing mechanism may rely on the hypotha-
lamic-pituitary-adrenal (HPA) axis, the
major driver of GC oscillations, and on
paracrine signaling within the adrenal
gland mediated by the opioid peptide
BAM22 and its receptor CXCR7 (Figure 1).
The HPA axis controls GC production in
the adrenal gland and its secretion into
the bloodstream through a cascade of
peptide hormones. Stimulated by the
hypothalamic hormone corticotropin re-
leasing factor (CRF), the pituitary secretes
adrenocorticotropic hormone (ACTH),
which activates the G-protein-coupled re-
ceptor melanocortin 2 receptor (MC2R) in
the adrenal cortex. The resulting intracel-
lular signaling cascade promotes GC
synthesis. Once secreted, GCs establish
a negative-feedback loop in the hypothal-
amus and the pituitary gland by inhibitingthe production of CRF and the secretion
of ACTH. This feedback loop and neuro-
endocrine connections between the
suprachiasmatic nucleus (SCN) and
CRF-producing cells in the hypothalamus
(Vrang et al., 1995) are thought to be
responsible for the daily oscillations of
GCs (Dickmeis, 2009; Kino, 2011). In
some cases, however, stress factors and
the associated physiological challenges
introduce some plasticity in plasma GC
concentrations. Imagine that you wake
up in the middle of the night several
days in a row because your cat keeps
jumping on your bed. Every time it
happens, the adrenal gland produces
bursts of GCs, and with time, the adrenal
gland develops a thicker cortex. This
adaptive reaction of the adrenal gland is
known as subcapsular cell hyperplasia
(SCH).
Initially identified as a lesion, SCH is his-
tologically different from tumors and is
considered a common outcome of adre-
nal tissue remodeling during aging (Aiba
and Fujibayashi, 2011). However, a phys-
iological role for SCH has not been pro-
posed thus far. Ikeda et al. observed
that mice with SCH have a normal period
length and phase of GC secretion, com-
bined with an unperturbed responsive-
ness to stress. However, in female mice
the amplitudes of daily GC oscillations
were increased at ZT12 (ZT: Zeitgeber
Time, the time after the lights are switched
on). Based on a battery of behavioral
tests, the higher amplitudes were causally
linked with enhanced anxiolytic effects.
Notably, this phenomenon is not ob-
served in SCH male mice, and the over-
confidence of the female mice was noCell 155, Dlonger observed when GCs amplitudes
were dampened using GC receptor inhib-
itors, in which case the scores of SCH
females were reduced to the level ob-
served in SCH males.
Like other steroid nuclear receptors,
the GC receptor has gender-specific
functions (Rando and Wahli, 2011). But
how does it make SCH females so brave?
In answering this question, Ikeda et al.
identify BAM22 and other opioid peptides
expressed in the adrenal gland of SCH
mice. Since subcapsular hyperplastic
cells express both the prohormone proen-
kephalin A and the corresponding conver-
tase furin, it is possible that opioids are
synthesized in situ and act as paracrine
factors for glucocorticoid-producing cells
(Figure 1). Consistent with this conjecture,
SCH mice with homozygous loss of the
proenkephalin A gene do not display an
improved score in anxiety tests. More-
over, in adrenal cell cultures, BAM22
activates the CXCR7 protein-G-coupled
receptor, leading to an increased GC
output. Interestingly, the phenotype is
exacerbated in cells treated concomi-
tantly with BAM22 and ACTH, suggesting
a synergistic effect between the opioid
and ACTH pathways. Finally, in SCH
female mice the stimulation of CXCR7
signaling with CCX771, a long-lived
CXCR7 receptor agonist, augmented the
daily amplitude of GC plasma levels
and affected the associated anxiolytic
behavior in a coherent manner. As antici-
pated, SCH male mice showed a blunted
response because CXCR7 was not effi-
ciently expressed in their adrenal cortex.
Thus, tissue remodeling occurring during
SCH may generate paracrine peptidesecember 5, 2013 ª2013 Elsevier Inc. 1211
Figure 1. CXCR7 Links Enhanced Glucocorticoid Amplitudes with Anxiolytic Behavior
In female mice, subcapsular hyperplasic cells (SCH) express proenkephalin A, which can be converted to
active opioid peptides by the processing enzyme furin. Once in the portal plexus, opioid peptides activate
the chemochine receptor CXCR7, which is expressed mainly in females, and promote glucocorticoid (GC)
synthesis, probably through amitogen activated protein kinase (MAPK) cascade. TheCXCR7 axis aligns in
phase with the HPA axis because only the amplitude, but not the other parameters, of GC oscillation is
modulated by the opioid peptide BAL22. Enhanced GC amplitudes are causally related to anxiolytic
performance through an undefined mechanism.that regulate GC amplitudes in addition to
the HPA axis (Figure 1).
As is always the case with papers re-
porting provocative findings, this study
raises a myriad of exciting issues remain-
ing to be addressed by future work.
For instance, it is still unclear whether
CXCR7 signaling oscillates in a diurnal
fashion. Similarly, it remains to be deter-
minedwhether CXCR7modulates plasma
GC concentrations by regulating their1212 Cell 155, December 5, 2013 ª2013 Elsesynthesis, stability, or secretion. As hy-
pothesized by the authors, the narrow
time window during which BAM22 en-
hances GC accumulation may insinuate
the involvement of local circadian clocks
in the adrenal cortex. If true, it would be
interesting to further elucidate the molec-
ular interplay between clock components
and CXCR7 signaling. One general theme
of this study is the cooperation between
acute signaling and ‘‘hard-wired’’ clockvier Inc.mechanisms in the regulation of cyclic
physiological processes. In order to main-
tain phase coherence within a tissue, the
cellular circadian oscillators must be
regularly synchronized by systemic cues
emanating from the master circadian
pacemaker in SCN. In the case of the
adrenal gland, neuronal and nonneuronal
pathways have been shown to be opera-
tive in this endeavor (Ishida et al., 2005).
The Zeitgeber properties of plasma GCs
for peripheral circadian oscillators (Balsa-
lobre et al., 2000; Pezu¨k et al., 2012)
opens the exciting possibility that these
steroid hormones may determine their
own amplitude in the blood by partici-
pating in the synchronization of the HPA
axis, local clocks in the adrenal gland,
and, as a consequence, the paracrine
signaling described here by Ikeda and
colleagues—resonating waves add up!REFERENCES
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